ASPIC

envie a um amigo share this

pmTOR is a marker of aggressiveness in papillary thyroid carcinomas

Catarina Tavares1,2,3, Maria João Coelho1,2,4, Miguel Melo1,2,5,6, Adriana Gaspar da Rocha1,2,7, Ana Pestana1,2,3, Rui Batista1,2,3, Catarina Salgado1,2, Catarina Eloy1,2, Luciana Ferreira1,2,3, Elisabete Rios3,8,9, Manuel Sobrinho-Simões1,2,3,8,9 and Paula Soares1,2,3,8

1-Instituto de Investigação e Inovação em Saúde (i3S), Universidade do Porto;

O pmTOR está relacionado com agressividade em carcinomas papilares da tiróide

Os carcinomas papilares da tiróide são, na sua grande maioria, tumores com muito bom prognóstico, sendo a cirurgia e posterior tratamento com iodo radioativo muitas vezes curativa. No entanto, uma pequena percentagem apresenta um comportamento mais agressivo, com recorrências locais e/ou metastização à distância, sendo que alguns desses casos acabam por desenvolver resistência ao tratamento com iodo radioativo.

Application of biodegradable ureteral stents as delivery vehicles for anti-cancer drugs in the treatment of upper urinary tract urothelial carcinoma

Drug eluting stents can release locally pharmaceutical active ingredients, particularly in the ureter and bladder, increasing the bioavailability and efficacy of the drugs. Although drug eluting stents has been widely used and commercially available in other fields, such as cardiology, its role in urology is limited. In his work, we propose the production of biodegradable stents using a simple technology, developed and patented by the team as drug new drug delivery devices, namely for the delivery of anti-cancer drugs for the treatment of upper urinary tract urothelial carcinoma.

Aplicação de cateteres ureterais biodegradáveis como veículos de libertação de fármacos para o tratamento de tumores do tracto superior do ureter

Os cateteres farmacológicos podem libertar compostos ativos que agem localmente no ureter ou bexiga aumentando assim a sua biodisponibilidade e eficiência. Embora a tecnologia com libertação de fármacos de cateteres esteja já comercialmente disponível noutros campos, tais como na cardiologia, o seu papel na urologia tem sido limitado.

Primary and Secondary Brain Tumors

CNIO Auditorium, Madrid, Spain

 

19 - 22 February, 2017

 

See more informations here: http://www.cnio.es/eventos/index.asp?ev=1&cev=136

Primary and Secondary Brain Tumors

CNIO Auditorium, Madrid, Spain

 

19 - 22 February, 2017

 

See more informations here: http://www.cnio.es/eventos/index.asp?ev=1&cev=136

1st International Symposium on Immune Responses in Cancer and Infection

Ecole Normale Supérieure de Lyon, Lyon, France

 

13 - 15 February, 2017

 

See more informations here: http://www.crcl.fr/654-1st-International-Symposium.crcl.aspx?language=fr-FR

1st International Symposium on Immune Responses in Cancer and Infection

Ecole Normale Supérieure de Lyon, Lyon, France

 

13 - 15 February, 2017

 

See more informations here: http://www.crcl.fr/654-1st-International-Symposium.crcl.aspx?language=fr-FR

32nd Ernst Klenk Symposium in Molecular Medicine - Precision oncology: Translating basic discoveries into patient survival

Main Lecture Hall of the Centers for Biochemistry and Physiology, Medical Faculty, University of Cologne, Cologne, Germany


08 - 10 December, 2016

 

See more informations here: http://www.cmmc-uni-koeln.de/events/ernst-klenk-symposium/ernst-klenk-symposium-2016/

32nd Ernst Klenk Symposium in Molecular Medicine - Precision oncology: Translating basic discoveries into patient survival

Main Lecture Hall of the Centers for Biochemistry and Physiology, Medical Faculty, University of Cologne, Cologne, Germany


08 - 10 December, 2016

 

See more informations here: http://www.cmmc-uni-koeln.de/events/ernst-klenk-symposium/ernst-klenk-symposium-2016/